GeneBio Systems
Recombinant Human PLA2G1B/PLA2 Protein (His Tag)
Recombinant Human PLA2G1B/PLA2 Protein (His Tag)
SKU:PKSH032899
Couldn't load pickup availability
Size: 50μg
Storage: Store at < -20°C, stable for 6 months. Please minimize freeze-thaw cycles.
Shipping: This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel packs. Upon receipt, store it immediately at < - 20°C.
Exp date: 12 months
Category ID_II: Recombinant Proteins
Category ID_III: Others
Abbreviation: PLA2G1B;PLA2
Target Synonym: Group IB phospholipase A2;PLA2;PLA2A;PLA2G1B;PPLA2;Phospholipase A2
Research Areas: Signal Transduction;Cancer;metabolism;
Conjugation:
Target Species: Human
Expression Host: HEK293 Cells
Application:
Fusion tag: C-His
UNIProt ID: P04054
Accession: P04054
Background: Phospholipase A2(PLA2G1B) is a secreted protein which belongs to the phospholipase A2 family. It catalyzes the release of fatty acids from glycero-3-phosphocholines. It catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. This releases glycerophospholipids and arachidonic acid that serve as the precursors of signal molecules. Sequences of pancreatic PLA2G1B enzymes from a variety of mammals have been reported. One striking feature of these enzymes is their close homology to venom phospholipases of snakes. Mice lacking in PLA2G1B are resistant to obesity and diabetes induced by feeding a diabetogenic high-fat/high-carbohydrate diet. Oral supplementation of a diabetogenic diet with the PLA2G1B inhibitor methyl indoxam effectively suppresses diet-induced obesity and diabetes. PLA2G1B inhibition may be a potentially effective oral therapeutic option for treatment of obesity and diabetes.
Concentration:
Activity: Not validated for activity
Sequence: Ala23-Ser148
Purity: > 95 % as determined by reducing SDS-PAGE.
Formulation: Supplied as a 0.2 μm filtered solution of 20mM Tris-HCl, 150mM NaCl, 10% Glycerol, pH 8.0.
Reconstitution: Not Applicable
Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.
Calculated MW: 15.2 kDa
ObservedMW: 17-20 kDa
